Slade Health

What Slade Health does

Slade Health is a specialty sterile pharmaceutical compounder operating five TGA-licensed (Australia) and Medsafe-licensed (New Zealand) facilities across Mount Waverley (VIC), Mount Kuring-gai (NSW), Geebung (QLD), Woodville (SA), and Avondale (Auckland). The company compounds patient-specific chemotherapy, antibiotics, analgesics, and Total Parenteral Nutrition (TPN) — the latter under an exclusive Australian manufacturing arrangement with Fresenius Kabi — and supplies more than 200 public and private hospitals across Australia and New Zealand, producing over 1.2 million infusions annually. It also provides clinical trial compounding services (345+ active trials, primarily oncology and haematology) and is the operator of a first-of-its-kind Australian Drug Stability Testing and Research Laboratory at Mt Kuring-gai that extends compounded drug shelf life from the standard 24 hours up to 90 days.

The technology stack centres on a proprietary bespoke compounding system, the SHOT (Slade Health Order Tracking) web platform for real-time chemotherapy ordering, and the SladeConnect customer portal. Slade has built native integration engines into the dominant hospital EMR/oncology information systems used in Australia and New Zealand — Magentus Charm Evolution, MOSAIQ, and Elekta ONE OIS — automating prescription ingestion and eliminating manual transcription and fax-based ordering. Slade is Australia's first licensed paperless compounder and holds ISO 27001 information security accreditation.

Slade Health is a wholly-owned subsidiary of Icon Group (Integrated Clinical Oncology Network Pty Ltd), generating revenue through B2B supply contracts negotiated via public tender processes. Commercial channels include direct enterprise sales to hospitals supported by Key Account Managers and a dedicated client relations team, multi-year exclusive sole supplier contracts at the state-government level (e.g., five-year SA public hospitals contract, renewed 2025), and a New Zealand public-private partnership with Te Toka Tumai Auckland / Health New Zealand. Digital distribution runs through SHOT and SladeConnect, with pricing negotiated privately per contract and not publicly disclosed.

Name

Slade Health

Legal name

Slade Health Pty Ltd

Website

https://sladehealth.com.au

Company type

Private

Founded year

1966

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Slade Health is a TGA-licensed sterile pharmaceutical compounder operating five facilities across Australia and New Zealand, supplying over 200 public and private hospitals with compounded chemotherapy, antibiotics, analgesics, TPN, and clinical trial products via its proprietary SHOT platform.

Ownership category

akta.pro rank

Product category

Sterile Pharmaceutical Compounding Services

NAICS

Ambulatory Health Care Services (621)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI)

Keywords

• Sterile pharmaceutical compounding
• Hospital pharmacy supply
• Chemotherapy compounding services
• Clinical trial manufacturing
• Total parenteral nutrition

Headquarters

HQ city

Mount Waverley

HQ country

Australia

HQ region

Oceania

Offices6 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure

Revenue model

1. Compounded Pharmaceutical Products (B2B Hospital Supply): Slade Health generates revenue by supplying compounded sterile pharmaceuticals (chemotherapy, antibiotics, analgesics, TPN) to hospitals under long-term contracts and public tender agreements. Revenue is derived from product supply to over 200 hospital partners across Australia and New Zealand. The company holds exclusive contracts such as the sole supplier agreement for South Australia's public hospitals and statewide contracts.
2. Clinical Trial Compounding Services: Slade provides compounding services for clinical trials (Phase I-IV, primarily oncology and haematology) for hospital partners. The service includes national clinical trial coordination, segregated storage of trial drugs, cold chain transport, and sponsor invoicing. Currently supporting over 345 clinical trials.
3. Digital Platform Services (SHOT, SladeConnect): Slade provides digital platforms (SHOT for order tracking and SladeConnect for product/clinical resources) to hospital and pharmacy partners, integrated into the core compounding service offering. These platforms streamline ordering, reduce errors, and improve operational efficiency, strengthening customer retention and contract renewals.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

Core offering

Slade Health is a TGA/Medsafe licensed sterile pharmaceutical compounder that prepares patient-specific chemotherapy, antibiotics, analgesics, and Total Parenteral Nutrition (TPN) for over 200 hospital partners across Australia and New Zealand from five licensed facilities. The company also provides clinical trial compounding services for Phase I-IV oncology and haematology trials and operates proprietary digital platforms (SHOT and SladeConnect) that integrate hospital EMR systems with Slade's bespoke compounding software for real-time order management.

Product overview

Slade Health is a specialized pharmaceutical compounding provider offering a unified portfolio of sterile compounding services across TGA-licensed facilities in Australia and New Zealand. The core offering consists of four main product lines: Chemotherapy Compounding, Antibiotics Compounding, Analgesics Compounding, and Total Parenteral Nutrition (TPN) Compounding (as exclusive Fresenius Kabi manufacturer). These are supported by Clinical Trials Compounding services and enabled by the Slade Health Order Tracking (SHOT) platform for real-time order management and SladeConnect for customer resources. The company operates five TGA-licensed facilities delivering over 1.2 million infusions annually to more than 200 hospital partners, with an Australian-first Drug Stability Testing Laboratory enabling extended shelf-life treatments.

Differentiator

Problem solved

Functional benefit

Products and services

• Chemotherapy Compounding Sterile compounding of patient-specific chemotherapy medications prepared under TGA licensed conditions for hospital oncology departments. Slade supplies over 200 hospitals nationally with real-time ordering and tracking through the SHOT platform, including same-day and emergency delivery for time-critical treatments.
• Antibiotics Compounding Sterile compounding of antibiotic medications for hospital use, including at-home intravenous antibiotic infusion via the Surefuser device for 24-hour continuous delivery to support hospital-in-the-home programs.
• Analgesics Compounding Sterile compounding of analgesic and pain relief medications, including pre-mixed formulations and theatre lines for hospital use across surgical and inpatient settings.
• Total Parenteral Nutrition (TPN) Compounding Exclusive Australian manufacturer of Fresenius Kabi Total Parenteral Nutrition (TPN). Compounds patient-specific and hospital-specific TPN formulations for both hospital and home use when gastrointestinal delivery is not possible.
• Clinical Trials Compounding Clinical trial support services from TGA/Medsafe licensed facilities, supporting Phase I-IV studies primarily in oncology and haematology. Includes national coordination across all five facilities, segregated storage of investigational products, validated cold chain transport, and sponsor invoicing. Currently supporting 345+ clinical trials with 8,000+ products made and 1,000+ trial patients reached in the last year.
• Slade Health Order Tracking (SHOT) Online chemotherapy management system providing real-time order tracking, online ordering, and order management for hospital pharmacists. Enables placement, tracking, review, and last-minute changes of chemotherapy orders with real-time visibility into order status, updates, and cancellations. Integrated with Charm Evolution, MOSAIQ, and Elekta ONE OIS hospital systems.
• SladeConnect Web-based digital hub providing hospital and pharmacy partners with secure access to product catalogues, stability information, educational resources, clinical resources, news, forms, and customer support. Available on desktop, tablet, and mobile, with mobile-optimized profiles for nurses.
• Drug Stability Testing and Research Laboratory
• Surefuser Infusion Pump Distribution Distribution of Nipro Surefuser at-home care infusion pump for safe and effective continuous medication delivery, including 24-hour intravenous antibiotic delivery in hospital-in-the-home settings. Slade also distributes the new one-day 240ml Surefuser+ for high viscosity antibiotics.

Quantifiable outcome

• Over 1.2 million infusions prepared annually
• +10 more outcomes

Named customers13 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

Feature7 records

Partnerships

Nine partnerships are on record, tiered minor and core.

• Pharmaxo Group (Icon acquisition)minorStrategic or Co-development Partner · 9 July 2024Icon Group acquired Pharmaxo Group, which provides specialist pharmaceutical products and clinical homecare to communities in the UK. Slade and Pharmaxo's combined experience aims to improve quality of care and ensure more timely access to specialised medications. Slade is part of Icon Group which includes Pharmaxo.
• Icon GroupcoreOthersSlade Health is part of Icon Group, Australasia's fastest growing cancer care provider. Icon Group encompasses Icon Cancer Centre, Slade Pharmacy, Epic Pharmacy, Icon Cancer Foundation, and international operations across New Zealand, Singapore, Malaysia, Indonesia, UK, and China. Slade Health provides compounding services to Icon Group's cancer care facilities.
• Magentus (Charm Evolution)coreTechnology or IntegrationSlade Health developed an integration engine connecting the Magentus Charm Evolution EMR system directly with Slade's bespoke compounding software. This enables automated data transfer eliminating manual faxes and emails, with real-time visibility into order status. Victoria (including Gippsland Health Alliance) and Queensland have adopted this digital solution.
• Elekta (Elekta ONE OIS / MOSAIQ)coreTechnology or IntegrationSlade Health integrated Elekta ONE OIS (powered by MOSAIQ) with its SHOT platform at Rockhampton Hospital, Bundaberg Hospital, and Hervey Bay Hospital. The integration automatically ingests customer orders and acts as a central hub for order management, available to all Slade hospital partners at no additional expense.
• GreenfleetminorStrategic or Co-development PartnerSlade Health partners with Greenfleet, a not-for-profit dedicated to protecting the climate and restoring native forests, for carbon offsetting. During the AdPha MM2023 Conference, Slade's initiative led to 150 native trees being planted, offsetting 94 tonnes of carbon emissions over their lifetimes.
• Nipro (Surefuser)minorOEM/ Whitelabel/ Licensing PartnerSlade Health distributes Nipro's Surefuser, a safe and effective at-home care infusion pump for delivering intravenous antibiotics over 24 hours. Slade also distributes the new one-day 240ml Surefuser+ for high viscosity antibiotics.
• Can AssistminorStrategic or Co-development PartnerSlade Health is a proud supporter of Can Assist, an organisation committed to ensuring that people living in rural and regional areas of NSW have access to cancer treatment and care. Slade also supports Cancer Council, Very Special Kids, Greenacres Disability Services, and Union for International Cancer Control (UICC).
• Fresenius KabicoreOEM/ Whitelabel/ Licensing PartnerSlade Health is the exclusive manufacturer of Fresenius Kabi's Total Parenteral Nutrition (TPN) in Australia. TPN is used when patients cannot support their own nutrition requirements via the gastrointestinal tract.
• Te Toka Tumai Auckland / Health New ZealandcoreStrategic or Co-development PartnerSlade Health operates the Avondale facility as part of a strong public-private partnership with Te Toka Tumai Auckland and broader Health New Zealand. Under this partnership, safer workflows, stronger medicine stewardship and connected care pathways have been established for patients across New Zealand.

Scale indicators12 records

Recent moves10 records

Expansion highlights7 records

Broad incumbents

• Baxter International: Large diversified hospital products company supplying IV solutions, injectable pharmaceuticals, and parenteral nutrition globally. Overlaps with Slade on compounded sterile products for hospitals but operates across a broader portfolio.
• B. Braun Melsungen AG: Global hospital products manufacturer supplying IV solutions, parenteral nutrition, and pharmacy compounding services; owns CAPS (US sterile compounder). Operates across Slade's product categories (TPN, IV, sterile compounding) at much larger scale.
• Sandoz: Global leader in generic injectable pharmaceuticals, including oncology and hospital injectables. Different operating model (large-scale batch manufacturing vs. patient-specific compounding) but addresses the same downstream hospital customer demand for sterile injectable medicines that Slade's compounded products complement.
• Pfizer (Hospital Injectables / CentreOne): Major manufacturer of generic injectable pharmaceuticals for hospitals (formerly Hospira business). Competes broadly with Slade in sterile injectable supply but at much larger global scale and across more therapeutic categories.
• Catalent, Inc. Global CDMO with sterile injectable fill/finish and clinical trial supply capabilities serving pharma and biotech. Comparable to Slade's clinical trial compounding service line (345+ trials) but operates at much larger scale and across biologics, oral solids, and consumer health categories.

Others

• Fresenius Kabi: Global parenteral nutrition manufacturer that supplies TPN products to Slade as exclusive Australian manufacturer of Fresenius Kabi TPN. Adjacent supplier/partner rather than direct competitor; comparable in TPN, IV, and clinical nutrition categories.

Direct peers

• QuVa Pharma: US sterile compounding pharmacy serving hospitals and health systems with ready-to-administer injectable preparations. Closely aligned to Slade's hospital supply model, multi-site sterile manufacturing footprint, and digital order integration thesis.
• ICU Medical: Manufacturer of sterile IV components, infusion pumps, and compounded injectable solutions for hospitals. Competes with Slade in sterile injectable supply for hospital customers with overlapping technology and EMR integration capabilities.
• CAPS (Central Admixture Pharmacy Services): US-based sterile admixture and compounding pharmacy services dedicated to hospital infusion needs. Operates a multi-site network similar to Slade's five-facility AU/NZ model and serves comparable B2B hospital customers with compounded sterile preparations.
• Pharmaxo Group (incl. Bath ASU): Sister company within Icon Group; UK-based provider of aseptic compounding services for hospitals and clinical homecare. Directly comparable to Slade's TGA/Medsafe-licensed sterile compounding model and now under common ownership, sharing capability development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/sladehealth
• LinkedInlinkedin.com/company/slade-health

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Slade Health